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Abstract
Introduction:  In  primary  immunodeﬁciencies  there  is  a  failure  in  the  anti-tumor  defense.  Com-
mon variable  immunodeﬁciency  (CVID)  is  one  of  the  most  common  primary  immunodeﬁciencies
characterized  by  an  alteration  in  the  differentiation  of  B  lymphocytes  (BL).  Epstein-Barr  virus
(EBV) is  an  ubiquitous  virus  that  selectively  infects  the  BL.  In  patients  with  immunodeﬁciency,
uncontrolled  proliferation  of  infected  BL  and  the  action  of  viral  proteins  promote  the  develop-
ment of  lymphomas.
Clinical  cases: At  the  University  Hospital  Sant  Joan  de  Deu,  Barcelona,  28  patients  were
diagnosed with  CVID  from  2000  to  2013.  This  paper  describes  four  patients  who  developed
non-Hodgkin’s  lymphoma  (NHL).  The  lymphoma  was  associated  with  EBV  in  two  of  the  cases.
Patients were  <  18  years  old,  diagnosed  with  lymphoma  between  4  and  13  years  old.  Two  patients
were treated  with  rituximab  as  monotherapy  and  achieved  complete  remission.  Two  patients
were treated  with  CHOP  (cyclophosphamide,  doxorubicin,  vincristine  and  prednisolone)  and
radiotherapy  or  rituximab  and  achieved  complete  remission.
Conclusions:  Early  detection  of  EBV  infections  and  NHL  in  all  patients  diagnosed  with  CVID  is
recommended,  regardless  of  age  at  diagnosis.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Resumen
odeﬁciencias  primarias  existe  un  fallo  en  la  defensa  antitumoral.
ble  común  (IDVC)  es  una  de  las  inmunodeﬁciencias  primarias  más
por  una  alteración  en  la  diferenciación  de  linfocitos  B  (LB).  El  virus
 virus  ubicuo  que  infecta  de  manera  selectiva  los  LB.  En  pacientes
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Introducción:  En  las  inmun
La inmunodeﬁciencia  varia
frecuentes.  Se  caracteriza  
de Epstein-Barr  (EBV)  es  un
con inmunodeﬁciencias,  la  
virales promueve  la  aparición  de  linfomas.
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Casos  clínicos:  En  el  Hospital  Universitario  Sant  Joan  de  Déu,  Barcelona,  se  han  diagnosticado
28 pacientes  con  IDVC  del  2000  al  2013.  En  este  trabajo  se  describen  cuatro  que  desarrollaron
linfoma no  Hodgkin  (NHL).  El  linfoma  fue  asociado  a  EBV  en  dos  de  ellos.  Los  pacientes  eran
menores de  18  an˜os,  con  el  linfoma  diagnosticado  entre  los  4  y  13  an˜os  de  edad.  Dos  de  los
pacientes  fueron  tratados  con  rituximab  como  monoterapia,  y  lograron  la  remisión  completa.
Dos fueron  tratados  con  CHOP  (ciclofosfamida,  doxorrubicina,  vincristina  y  prednisolona)  y
radioterapia  o  rituximab  y  también  alcanzaron  la  remisión  completa.
Conclusiones:  Se  recomienda  realizar  la  detección  precoz  de  las  infecciones  por  EBV  y  los  NHL
en todos  los  pacientes  con  diagnóstico  de  IDVC,  independientemente  de  la  edad  del  diagnóstico.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t1. Introduction
Immunodeﬁciencies  are  a  very  broad  group  of  diseases  with
different  pathogenetic  mechanisms,  which  have  in  com-
mon  a  failure  in  the  regulation  of  the  immune  defense
against  foreign  aggressions.  This  failure  in  the  regulation
gives  rise  to  diseases  whose  origin  could  be  in  the  alter-
ation  of  a  receptor  (for  example,  TOLL  type),  in  the  absence
of  an  interleukin  (IL),  in  the  lack  of  function  of  the  B
lymphocytes  (BL)  or  T  lymphocytes  (TL)  or  in  the  lack  of
a  protein  such  as  MBL  (mannose-binding  lectin).  In  the
end,  whatever  the  inductor  genetic  failure,  the  predomi-
nant  symptomatology  is  the  presence  of  infections,  although
these  patients  also  have  cancers  of  lymphoid  origin  and
autoimmune  diseases.1,2 Immunodeﬁciencies  are  classiﬁed
into  two  categories:  i)  congenital  or  primary,  almost  always
due  to  mutations  or  deletions  of  genes  that  tend  to  be  hered-
itary  but  can  also  be  de  novo  mutations;  and  (ii)  acquired
or  secondary  due  to  a  disease  that  facilitates  the  loss  of
antibodies  or  lymphocytes.  Primary  immunodeﬁciencies  are
associated  with  the  genetic  deﬁciencies  mentioned  above.
Examples  of  diseases  that  promote  secondary  deﬁciencies
are  persistent  infections  such  as  malaria,  chronic  diarrhea
or  nephrotic  syndrome.3 Currently  there  have  been  >  70  clin-
ical  forms  of  primary  immunodeﬁciencies  identiﬁed.  Due  to
recent  advances  in  molecular  biology,  the  molecular  defects
responsible  for  an  important  part  of  the  primary  immunode-
ﬁciencies  are  known,  with  undeniable  advantages  in  terms  of
the  possibility  of  an  accurate  diagnosis,  prenatal  diagnosis  in
affected  families,  genetic  counseling  and,  in  some  cases,  the
possibility  of  treatment  through  gene  therapy  (Table  1).4,5
1.1.  Immunity  and  cancer
The  relationship  between  immunity  and  cancer  is  well
known.  Tumor  cell  antigens  induce  effector  immune
responses  that  destroy  tumor  cells.  An  immunological
approach  is  increasingly  used  for  the  diagnosis  and  treat-
ment  of  cancer.
The  immune  defense  against  cancer  is  initially  mediated
by  innate  immunity,  composed  of  natural  killer  (NK)  cells
capable  of  destroying  tumor  cells.  This  function  potenti-
ates  with  interleukins  2  and  12  (IL-2,  IL-12)  and  interferons.
Macrophages  eliminate  tumor  cells  using  the  same  mech-
anisms  that  eliminate  bacteria.  Activated  macrophages
o
t
l
fynthesize  tumor  necrosis  factor  (TNF)  that  produces  throm-
osis  of  the  tumor  blood  vessels.  Antitumor  adaptive
mmunity  is  fundamentally  mediated  by  LT  CD8  +  ,  which
re  cytotoxic  lymphocytes  sensitized  against  tumor  antigens
apable  of  destroying  cancer  cells.  This  speciﬁc  cytotoxic
ffector  function  starts  with  antigen-presenting  cells  (den-
ritic  cells)  and  is  potentiated  by  stimuli  of  the  LT  CD4  + .
daptive  humoral  immunity  consists  of  speciﬁc  IgG  anti-
odies  against  tumor  antigens,  but  usually  has  no  effector
unction  against  the  tumor  and  only  serves  for  the  diagnosis
nd  control  of  tumor  evolution.6
.2.  Epstein-Barr  virus  (EBV)  and  lymphomas
BV  is  a  double-stranded,  ubiquitous  DNA  virus  belonging  to
he  herpesvirus  family,  which  selectively  infects  BL,  persist-
ng  in  a latent  state.  EBV  antigens  are  expressed  differently,
epending  on  the  stage  of  differentiation  of  the  BL  and  have
ifferent  activity.  These  viral  antigens  are  expressed  in  the
ucleus,  cytoplasm  and  surface  of  infected  cells.  The  ﬁrst
ntigens  found  in  a  latent  infection  are  the  Epstein--Barr
uclear  antigens  (EBNAs)  of  which  EBNA-LP,  EBNA-2,  EBNA-
A,-3B  and  -3C  are  known  and  whose  function  is  the  stimulus
f  BL  proliferation.  Latent  membrane  proteins  -1  and  -2
LMP-1  and  LMP-2)  have  oncogenic  properties  because  they
acilitate  genomic  instability  and  promote  the  immortal-
zation  and  transformation  of  the  infected  BL.  EBV  is  a  BL
olyclonal  activator,  independent  of  the  TL  cooperating  sig-
als  or  dendritic  cells.  The  in  vitro  BL  infection  promotes  the
ormation  of  lymphoblastoid  cell  lines  (LCL)  immortalized
ue  to  the  expression  of  the  EBNA,  LMP  proteins  and  various
on-coding  miRNAs.  LMP1  and  LMP2A  act  as  constitutively
ctive  receptors  that  imitate  the  CD40  signals  of  differen-
iation  and  of  the  BL  antigen  receptor,  respectively.  By  this
echanism,  EBV  appropriates  the  physiological  pathway  of
ctivation  of  the  BL  and  promotes  its  proliferation  and  dif-
erentiation  to  memory  cells  in  which  the  virus  may  persist
or  the  lifetime  of  the  infected  individual.7
When  a  poor  cytotoxic  TL  CD8  +  response  occurs  due  to
n  immunodeﬁciency  of  any  type,  an  uncontrolled  prolifera-
ion  of  infected  BL  takes  place  that  increases  the  probability
f  errors  occurring  during  DNA  replication,  including  some
hat  affect  the  oncogenes  or  tumor  suppressor  genes.  The
oci  of  the  immunoglobulins  are  the  most  susceptible  to  suf-
er  translocations.  Translocation  of  the  MYC  gene  to  the
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Table  1  Principal  characteristics  of  primary  immunodeﬁciencies.
Form  of  PID  Examples  of  diseases  Age  at
initiation
Infectious  complications  Other  manifestations
Predominant  antibody
immunodeﬁciency
(humoral)
•  X-linked  or  Bruton
agammaglobulinemia
and  AR  form
• Transitory  hypogam-
maglobulinemia  of
infancy
• CVID
•  Selective  defect  of
Ig (IgA)
>  6  months
Can  debut  in
adolescence  or
during
adulthood
•  Sinopulmonary
infections  by
encapsulated  bacteria
(pneumococcus  H.
inﬂuenzae)
• Gastrointestinal
infections  due  to  Giardia
lamblia,
Cryptosporidium,  and
enterovirus  (the  latter
especially  in  X-linked
agammaglobulinemia)
• Meningoencephalitis  due
to echo  virus  in  X-linked
agammaglobulinemia
•  Autoimmunity:
formation  of
auto-antibodies  and
intestinal
inﬂammatory  disease
•  Can  be  the  primary
manifestation  of  CVID
• Allergic  disorders
•  Lymphoproliferative
syndrome
• Vaccine  viral
disease
Combined
Immunodeﬁciencies
(humoral and  cellular)
•  SCID  due  to  defect
in Jak3,  RAG,  ADA
• Reticular  dysgenesis
• Omenn  syndrome
•  Hyper-IgM  syndrome
<  6  months  of
life
•  Respiratory,
gastrointestinal  and  skin
infections  due  to
opportunistic  germs:
-bacteria,
-mycobacteria,
-virus  (EBV,  CMV,  VVZ,
enterovirus)
-fungus  (Candida,
Aspergillus)
-Pneumocystis  jiroveci
•  Developmental
delay
• Atopic  dermatitis
•  Vaccine  viral
disease
Defects of  phagocytes  •  Congenital
neutropenia
(Kostmann  syndrome)
• Cyclic  neutropenia
• Leukocyte  adhesion
defect
• Chronic
granulomatous
disease
Newborn  or
infancy
•  Infections  in  skin,  lungs,
and in  the
reticuloendothelial
system  (liver,  spleen)  due
to germs:
-bacteria  (mainly
staphylococcus,
Pseudomonas,
enterobacteria)
-fungus
•  Defect  in
cicatrization
• Late  falling  off  of
the  umbilical  cord
• Formation  of
granulomas  and
abscesses
• Oral  thrush
(neutropenia)
Complement defect  •  Defect  C3
•  Defect  C5-C9
Any  age  •  Infections  due  to  Gram
positive  bacilli  (defect  C3)
• Infections  due  to
Neisseria  (defect  C5-C9)
•  Lupus-like  syndrome
(in  C2-C4  defect
without  infectious
manifestations  and  in
C5-C9  defect)
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CPID, primary immunodeﬁciency; ID, immunodeﬁciency; AR, autos
deﬁciency; EBV, Epstein-Barr virus; CMV, cytomegalovirus; VZV, va
ocus  of  the  immunoglobulins  gives  rise  to  an  abnormal
YC  expression  associated  with  the  malignant  transforma-
ion  and  uncontrolled  proliferation  of  neoplastic  BL  clones,
hich  will  constitute  B-cell  lymphoma.  However,  it  is  known
hat  in  patients  with  immune  deﬁciencies  without  MYC
ranslocations  the  viral  proteins  are  sufﬁcient  to  stimu-
ate  the  production  of  BL  clones  that  make  up  the  B
ymphomas.8,9
a
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d recessive; Ig, immunoglobulin; SCID, severe combined immuno-
a-zoster virus.
In  situations  of  immune  competence,  tumor  cells  are
liminated  by  the  defense  mechanisms  described  and  the
irus  persists  asymptomatically,  turning  off  its  expression.
ongenital  and  secondary  or  acquired  immunodeﬁciencies
re  important  risk  factors  for  developing  neoplasms.  In
igure  1 and  Table  2  the  risk  of  leukemias  and  lym-
homas  in  diseases  accompanied  by  immunodeﬁciency  are
escribed.
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tFigure  1  Immunodeﬁciency  and  risk  of  non-Hodgkin  lym-
phoma.
1.3.  Common  variable  immunodeﬁciency  and
lymphomas
In  the  Hospital  Universitario  Sant  Joan  de  Déu  (HUSJD)  the
highest  frequency  of  neoplasms  in  children  with  primary
immunodeﬁciency  has  been  detected  in  patients  with  com-
mon  variable  immunodeﬁciency  (CVID)  and  in  all  cases  has
been  associated  with  B  cell  lymphomas.10,11
CVID  is  a  primary  immunodeﬁciency  characterized  by  an
alteration  in  the  differentiation  of  B  cells,  with  a  decrease  in
the  production  of  immunoglobulins.  It  is  the  most  prevalent
form  of  severe  antibody  defects  that  presents  itself  at  a  rate
of  1/25,000  to  1/60,000  individuals.12 CVID  encompasses  a
heterogeneous  mixture  of  disorders  due  to  immunoglobulin
and  Toll-like  receptors  (TLR9  and  TLR7)  deﬁcits  that  trans-
late  in  lack  of  stimulation  of  dendritic  cells  and  interferon
alpha  production,  fundamental  mediators  in  the  initiation
of  the  antitumoral  innate  immunological  defense.  Clinical
manifestations  are  also  heterogeneous  and  include  recur-
rent  infections  (in  almost  100%  of  patients),  chronic  lung
disease  (30-50%),  autoimmune  diseases  (25%),  gastrointesti-
nal  diseases  (20%),  allergic  disease  (33%)  and  elevated
susceptibility  to  develop  lymphomas.  Disease  initiation  is
typically  described  after  puberty  and  before  the  age  of  30
years,  although  there  is  a  bimodal  distribution  with  a  peak
between  1  and  5  years  and  another  between  18  and  25  years.
Table  2  Congenital  diseases  associated  with  an  increased
risk of  leukemia  or  lymphoma.
Disease  Risk*
Down  syndrome  1/74  before  10  years
Fanconi  syndrome  1/12  before  21  years
Bloom  syndrome  1/8  before  26  years
Ataxia-Telangiectasia  12/100
Wiskott-Aldrich  syndrome  12/100
IgA deﬁciency  Unknown
Healthy  population  1/3000  before  15  years
* Risk is calculated based on the number of people suffering
from leukemia or lymphoma divided by the number of patients
with congenital diseases. It is compared against the risk of
leukemia or lymphoma in the healthy population (without risk
factors).
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iagnosis  of  the  disease  is  established  by  clinical  and  ana-
ytical  criteria  and  after  making  a  differential  diagnosis  with
ther  diseases  presenting  with  hypogammaglobulinemia.13
ince  2003,  mutations  in  four  genes  associated  with  CVID
ave  been  described,  which  would  represent  10-15%  of
he  cases.  The  mutations  described  in  three  of  the  genes
resent  an  autosomal  recessive  inheritance  pattern  and  are
xtremely  rare:  deﬁcit  in  the  inducible  co-stimulator  of  acti-
ated  T-cells  (ICOS),  CD19  deﬁcit  and  deﬁcit  in  the  B-cell
ctivating  factor  (BAFF-R).  The  fourth  group  corresponds
o  mutations  in  the  TNFRSF12B  gene  (TACI)  described  in
p  to  10%  of  patients  with  CVID,  with  an  autosomal  dom-
nant,  autosomal  recessive  or  complex  inheritance  pattern
healthy  relatives  who  are  carriers  of  the  mutation  have
een  found).14
Because  it  is  a  very  heterogeneous  disease  its  progno-
is  is  very  variable.  There  are  patients  in  whom  infections
redominate  and  are  easier  to  treat  and  respond  well  to
eplacement  therapy  with  subcutaneous  or  intravenous  gam-
aglobulin.  Another  group  of  patients  have  more  frequent
utoimmune  diseases.  In  the  experience  of  the  HUSJD,
he  most  common  autoimmune  diseases  in  patients  with
VID  are  type  1 diabetes  mellitus,  thyroiditis,  celiac  dis-
ase,  systemic  lupus  erythematosus  and  vitiligo;  sometimes
everal  of  these  diseases  coexist  in  the  same  patient.  In
hese  children,  treatment  with  gammaglobulin  does  not
dequately  control  the  autoimmune  disease  that  requires
mmunosuppressant  or  substitutive  treatment  of  the  dis-
ase  itself.  Children  with  neoplasms  (lymphomas)  have  a
rognosis  derived  from  the  optimal  therapeutic  response  to
he  anti-CD20  (rituximab)  monoclonal  antibodies.  Cytostatic
reatment  is  necessary  in  cases  in  which  there  is  no  response
o  rituximab.
Regarding  the  prognosis,  it  should  be  kept  in  mind,  as  a
hole,  that  treatment  with  gammaglobulin  therapy  reduces
he  number  of  infections,  hospitalizations  and  improves
uality  of  life.  However,  it  has  not  been  shown  to  pro-
ect  from  the  development  of  neoplasms  or  non-infectious
omplications,  such  as  autoimmune  diseases  or  granuloma-
ous  disease.
.  Clinical cases
n  the  experience  of  the  HUSJD  in  Barcelona,  Spain  the
ighest  frequency  of  neoplasms  in  children  with  primary
mmunodeﬁciency  has  been  detected  in  patients  with  CVID,
nd  in  all  cases  the  neoplasms  have  been  B  cell  lymphomas.11
he  experience  in  regard  to  B  cell  lymphomas  in  chil-
ren  diagnosed  with  CVID  in  the  HUSJD  is  described  below.
etween  the  years  2000  and  2013  there  were  28  children
etected  with  CVID,  diagnosed  according  to  the  criteria  of
he  European  Society  for  Immunodeﬁciencies  (ESID)  and  the
an  American  Group  of  Immunodeﬁciencies  (PAGID).15 Of  the
8  children  with  CVID,  four  had  B  cell  lymphomas,  two  of
hem  associated  with  EBV.
.1.  Case  1e  present  the  case  of  a Caucasian  male  patient.  At  2
onths  of  age  he  had  chickenpox  without  complications.
fter  12  months  of  age  he  had  mumps,  bronchitis,  otitis
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edia,  and  recurrent  conjunctivitis.  At  2  years  of  age  he
nderwent  tonsillectomy  and  adenoidectomy  for  persistent
titis.  Multiple  eye  and  ear  cultures  were  done,  which  were
ositive  for  Haemophilus  inﬂuenzae, Streptococcus  pyo-
enes,  Streptococcus  pneumoniae, Pseudomonas  aeruginosa
nd  Staphylococcus  aureus  at  4  years  of  age.  At  this  same
ge  he  had  mononucleosis  syndrome  due  to  cytomegalovirus
CMV).  At  5  years  of  age  he  was  diagnosed  with  CVID.
reatment  with  intravenous  immunoglobulins  was  begun.
e  continued  to  have  recurrent  respiratory  tract  infections
espite  having  correct  levels  of  IgG.  He  demonstrated  a  lag
n  weight/height.
At  8  years  of  age  he  developed  persistent  cervical  and
nguinal  adenitis.  Biopsy  of  the  inguinal  lymph  node  showed
vidence  of  follicular  hyperplasia  and  PCR  was  positive  for
BV.  At  12  years  of  age  he  presented  a  new  episode  of  per-
istent  cervical  adenitis.  Biopsy  of  the  cervical  adenopathy
onﬁrmed  a  marginal  non-Hodgkin’s  lymphoma  (NHL)  with
CR  positive  for  EBV.  NHL  was  immunophenotype  positive  for
D20  and  CD79.  The  extension  study  was  negative.  He  was
lassiﬁed  as  stage  III  due  to  the  pathological  characteristics
f  the  lymph  nodes  on  computed  tomography  (CT).  Treat-
ent  with  rituximab  at  a  dose  of  375  mg/m2 was  decided
pon  with  a  ﬁrst  induction  cycle  of  four  weekly  doses,  fol-
owed  by  a  phase  of  consolidation  with  four  doses  at  monthly
ntervals  and  ﬁnally  the  maintenance  phase  with  two  doses  a
onth  until  2  years  of  treatment  were  completed.  Complete
emission  was  obtained.
The  patient  has  maintained  normal  or  elevated  IgM  lev-
ls,  ranging  between  500  and  1700  mg/dl  up  to  10  months
fter  the  initiation  of  rituximab.  Hyper-IgM  syndrome  was
uled  out  due  to  the  correct  expression  of  CD40  and  CD40L
nd  absence  of  genetic  mutations,  and  X-linked  lymphopro-
iferative  syndrome  due  to  the  absence  of  mutations  in  the
H2D1A  and  XIAP  genes.
.2.  Case  2
e  present  the  case  of  a  female  African-American  patient
ho  presented  with  chronic  diarrhea  of  unknown  origin
nd  somatic  developmetal  delay  from  early  infancy.  At
he  age  of  8  years  she  was  transferred  to  Spain  and
t  that  age  was  diagnosed  with  CVID.  Physical  exami-
ation  revealed  splenomegaly,  pallor,  cervicolateral  lym-
hadenopathy,  bilateral  lung  rales,  hypogammaglobulinemia
nd  anemia.  After  immunological  study  that  showed
ecrease  in  isohemagglutinins  and  IgG,  IgM  and  IgA,  she
as  diagnosed  with  CVID  and  treatment  was  begun  with
ntravenous  immunoglobulins.  Minimal  duodenal  lesions  and
ymphocytic  inﬂammatory  inﬁltration  were  noted  on  intesti-
al  biopsy.  Pulmonary  function  showed  a  mixed  obstructive
nd  restrictive  pattern  without  response  to  bronchodila-
ors.  Lung  CT  showed  multiple  bilateral  parenchymal  and
ubpleural  nodules,  hilar  lymphadenopathy,  and  mediastinal
nd  axillary  lymphadenopathy.  Lung  biopsy  conﬁrmed  low-
rade  lymphoma  of  marginal  zone,  PCR  positive  for  EBV  and
lassiﬁed  as  stage  II.  Extension  study  was  negative.  She  was
reated  with  rituximab  as  in  Case  1,  with  complete  remis-
ion.
She  persisted  with  chronic  diarrhea  due  to  the  presence
f  colon  ulcers  with  PCR  positive  for  CMV  on  biopsies.  At  14
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ears  of  age  she  presented  enterocolitis  with  poor  response
o  different  treatments  that  required  total  colectomy
ith  ileostomy.  Histological  analysis  showed  indeterminate
nﬂammatory  disease.  Currently,  at  the  age  of  16  years,
he  remains  stable,  with  secondary  osteoporosis  and  lung
unction  with  mixed  pattern.
During  the  diagnosis  of  CVID,  the  percentage  of  B  cells
n  peripheral  blood  was  11%,  and  3  years  after  rituximab
s  from  0-2%.  Bruton  gammaglobulinemia  was  ruled  out  by
egativity  of  mutations  in  the  Bruton  tyrosine  kinase  gene
BTK).
.3.  Case  3
e  present  the  case  of  a  Caucasian  male  with  an  intense
out  of  chickenpox  at  18  months  of  age  and  recurrent  bron-
hitis  until  3  years  of  age.  At  4  years  of  age  he  was  diagnosed
ith  abdominal  Burkitt  lymphoma  with  liver  and  central  ner-
ous  system  metastasis  (brain  and  leptomeninges),  classiﬁed
s  stage  IV.  Chemotherapy  was  administered  (vincristine,
yclophosphamide  and  prednisone,  methotrexate,  ARA-C
nd  intrathecal  hydrocortisone)  along  with  cranial  and  spinal
adiotherapy.  After  the  initiation  of  chemotherapy  he  devel-
ped  herpes  zoster.  At  6  years  of  age  he  was  diagnosed
ith  CVID  and  was  started  on  replacement  therapy  of  intra-
enous  immunoglobulins.  The  patient  had  low  stature  due
o  growth  hormone  deﬁciency,  probably  secondary  to  skull
adiation.  He  had  bronchial  asthma  from  7  years  of  age  and
llergic  rhinoconjunctivitis  caused  by  seasonal  allergies  to
ild  grasses.  Currently,  at  13  years  of  age  he  is  clinically
table,  without  infections  or  relapses  of  lymphoma.  He  con-
inues  with  low  stature  and  respiratory  allergy.  There  is  no
nformation  with  regard  to  the  EBV  status.
.4.  Case  4
e  present  a  female  Caucasian  patient  with  tonsillitis,  otitis
nd  pneumonia  between  3  and  4  years  of  age  and  adenoidec-
omy  at  5  years  of  age.  At  11  years  of  age  she  presented  with
n  inguinal  tumor  diagnosed  as  stage  II  marginal  low  grade
-cell  NHL.  Immunohistochemical  study  of  the  lymph  nodes
howed  weak  expression  of  CD20,  CD45  and  CD43  and  pos-
tive  follicular  expression  for  bcl-2  and  negative  for  CD10
ruling  out  follicular  lymphoma).  There  was  monotypical
xpression  of  kappa  chains  and  interfollicular  plasmacytoid
ifferentiation,  without  expression  of  cyclin  D1  (ruling  out
antle  lymphoma).  With  in  situ  hybridization  there  were  no
ranslocations  detected  (14;18)  or  (11;14).  Anti-EBV  IgG  pos-
tive  antibodies  were  found  in  plasma.  CHOP  chemotherapy
as  begun  (cyclophosphamide,  doxorubicin,  vincristine  and
rednisone)  every  21  days  for  6  cycles.  Complete  remission
as  obtained.
At  13  years  of  age  she  developed  autoimmune  hemolytic
nemia  difﬁcult  to  control  with  steroids  and  which  required
wo  cycles  of  rituximab  (375  mg/m2/week,  4  weeks),  with
pace  of  6  months  between  relapses.  At  age  15  years,
 year  after  completing  rituximab,  she  developed  B  lym-
hopenia  and  persistent  panhypogammaglobulinemia.  The
tudy  for  autoimmune  lymphoproliferative  disease  was  pos-
tive  and  she  was  diagnosed  with  CVID.  Treatment  was
egun  with  intravenous  immunoglobulins.  Subsequently  she
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Table  3  Clinical  and  laboratory  characteristics  associated  with  CVID  patients  who  develop  NHL.
Patient  1  Patient  2  Patient  3  Patient  4
Gender  Male  Female  Male  Female
Consanguinity  No  Yes  No  No
Family history
- immunodeﬁciency  No  No  No  No
- autoimmunity  Yes  No  No  Yes
- malignancy  Yes  No  Yes  Yes
1st symptom  (age)  Infection  (1  y)  Chronic  diarrhea  (1  y)  Failure  to  thrive  (4  y)  Lymphoma  (11  y)
Age at  CVID  diagnosis  5  y  11m  8  y  6  y  3  m  15  y  11  m
Phenotypes
No other  disease-related  complications No  No  Yes No
Cytopenias  No  No  No  Yes
Polyclonal lymphoproliferation  Yes  No  No  No
Unexplained  persistent  enteropathy  No  Yes  No  No
EUROClass group  smB  +  21loTrnorm smB-  smB  +  21lo B  +
Pediatric classiﬁcation  Group  II  Group  I Group  II  Unknown
IgM (mg/dL)  at  CVID  diagnosis* 1700  55  347  98
**Gen  TNFRSF  13B
- exons  1→5 No  mutations No  mutations ---- ----
- variant  A,  NS  Heterozygous  Heterozygous  Heterozygous  Homozygous
- variant  B,  NS  ----  ----  ----  Heterozygous
*Gen  LRBA
-  variant  A,  NS  ----  Homozygous  ----  ----
- variant  B,  NS  ----  Homozygous  ----  ----
- variant  C,  stop  gain  ----  Homozygous  ----  ----
- variant  F,  NS  ----  ----  Heterozygous  ----
*Gen  ICOSLG
-  variant  NS  Heterozygous  ----  ----  ----
y, year; m, month; NS, nonsynonymous.
*
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** Total IgM in mg/dl at diagnosis.
presented  with  cervical  and  inguinal  adenitis  and  after  a
positron  emission  tomography  (PET)  and  inguinal  and  axil-
lary  biopsies  were  done,  reactive  lymphoid  hyperplasia  was
reported.  At  16  years  of  age  she  developed  right  sub-
mandibular  lymphadenopathy,  conﬁrmed  by  biopsy  to  be
MALT  type  marginal  lymphoma.  EBV  was  negative  for  in  situ
hybridization  and  latent  membrane  protein  was  also  nega-
tive  by  immunohistochemistry.  Treatment  was  administered
with  rituximab.  At  18  years  of  age  she  was  transferred  to
an  adult  treatment  center  due  to  a  recurrence  of  the  MALT
lymphoma.  Tables  3  and  4  summarize  the  clinical,  laboratory
characteristics,  type  of  lymphoma  and  treatment  given.
3. Discussion
Four  children  diagnosed  with  CVID  who  developed  NHL  are
described.  Some  patients  presented  here  have  been  previ-
ously  described 11.  Lymphoma  was  associated  with  EBV  in
two  of  the  children.  In  addition,  two  patients  developed
lymphoma  prior  to  diagnosis  of  CVID.
Complications  of  the  CVID  include  an  increased  risk  of
malignancy,  especially  lymphoma  and  gastric  cancer.16--19
Lymphoma  can  be  considered  one  of  the  most  serious
p
1
d
complications  of  CVID.  The  cause  of  the  increased  risk  of
ymphoma  in  CVID  seems  to  be  multifactorial  where  the
nteraction  of  chronic  infections,  regulation  of  the  immune
ystem  and  genetic  disorders  facilitate  the  development  of
he  malignant  transformation.20
Kinlen  et  al.21 reported  a  30-fold  increase  in  the  risk
f  developing  lymphoma  in  CVID,  whereas  Cunningham-
undles  et  al.17 reported  an  increase  of  260-fold.  Results
f  the  data  registry  of  Sweden  and  Denmark  showed  an
ncrease  of  12  times  in  the  risk  of  lymphoma.22 The  Ital-
an  study  of  Quinti  et  al.  supports  an  increase  of  18  times
igher  in  the  risk  of  lymphoma,  with  four  cases  of  NHL  during
 years.12 The  Australian  study  with  416  patients  reported  a
tandardized  incidence  rate  (SIR)  of  12.1  for  each  1.132  of
HL  patients  (95%  CI:  6.03-21.0).18
Lymphomas  that  occur  in  patients  with  CVID  are  most
ommonly  of  B-cell  origin.  There  is  a  predominance  of  NHL,
enerally  from  the  fourth  to  the  seventh  decade  of  life
nd  rarely  in  children.  It  is  commonly  extranodal  and  EBV
egative.23 A  retrospective  study  of  lymph  node  biopsies  of
atients  with  primary  immunodeﬁciencies  showed  that  16  of
9  samples  were  positive  for  lymphoma  and  were  patients
iagnosed  with  CVID.24 The  majority  were  NHL  with  only  one
ase  of  Hodgkin’s  disease  and  EBV  was  not  found  in  any  of  the
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Table  4  Lymphoma  characteristics,  treatment  and  outcome.
Patient  1  Patient  2  Patient  3  Patient  4
Gender  Male  Female  Male  Female
Age* 12  y 8  y  4  y  7m  11  y  11  m
Type NHL NHL  NHL  NHL
Lymphoma  subtype MALT MALT Burkitt  MALT
Staging Stage  III  Stage  II  Stage  IV  Stage  II
EBV tumor  status:  ----  ----  ----  ----
-In situ  hybridization  +  −  unknown  −
-PCR +  +  unknown  −
EBV status  plasma:  PCR-  PCR  +  (whole  blood)  IgM  EBV-  IgG  EBV  +
Primary site  Cervical  lymphadenopathy  Pulmonary  Diffuse  Abdominal  Inguinal  lymphadenopathy
Therapy Rituximab  Rituximab  CHOP,  Rx  CHOP
Outcome Remission  Remission  Remission  Recurrence
Therapy recurrence  ----  ----  ----  Rituximab
* Age at lymphoma diagnosis.
ssoc
apy.
i
c
4
p
i
p
m
b
i
e
h
n
a
a
H
i
s
e
p
T
c
p
C
p
t
g
w
w
i
n
a
p
m
r
i
r
T
w
r
p
n
a
i
N
d
w
a
E
P
d
a
C
d
R
d
C
T
Ry, years; m, month; NHL, non-Hodgkin lymphoma; MALT, mucosa-a
phamide, doxorubicin, vincristine, prednisone; Rx, radiation ther
n  situ  samples  by  hybridization.  Patients  of  this  study  were
hildren  <  18  years  with  the  lymphoma  diagnosed  between
 and  13  years  of  age  (4  years  of  age  for  the  Burkitt’s  lym-
homa  and  from  10  to  13  years  for  MALT  lymphoma).  The
n  situ  hybridization  for  EBER1  of  the  EBV  was  positive  in
atient  1  and  negative  in  patients  2  and  4.  There  is  no  infor-
ation  available  on  patient  3.  EBV  was  found  by  PCR  in  the
iopsies  of  patients  1  and  2.
The  role  of  different  members  of  the  herpesvirus  fam-
ly  has  been  investigated  in  patients  with  CVID.  Wheat
t  al.  reported  an  important  ﬁnding:  the  presence  of  the
uman  herpesvirus  8  (HHV-8)  in  six  of  the  nine  patients  diag-
osed  with  CVID  with  interstitial  granulomatous  lung  disease
nd  lymphoma  (GLILD).25 One  patient  developed  NHL  and
nother  developed  MALT  lymphoma.  In  the  ﬁrst  patient  the
HV-8  virus  was  found  by  qRT-PCR  in  a  high  number  of  copies
n  the  malignant  lymph  nodes.  Patient  2  of  our  cases  had  PCR
tudy  for  pulmonary  biopsy  negative  for  HHV-8.  Raeiszadeh
t  al.  found  an  increase  of  CD8  +  T  cells  speciﬁc  for  CMV
eptides  in  patients  with  CVID  compared  with  controls.26
heir  observation  was  related  with  a  higher  prevalence  of
olitis  and  subsequent  development  of  NHL.  In  our  series,
atient  1  was  diagnosed  with  infectious  mononucleosis  by
MV  before  the  CVID  and  the  lymphoma.  Patient  2  had  PCR
ositive  for  CMV  in  colon  biopsies  years  before  lymphoma
reatment.
Treatment  of  immunocompetent  patients  with  non-
astric  MALT  lymphoma  usually  includes  immunotherapy
ith  monoclonal  antibodies  directed  to  CD20  (rituximab)
ith  or  without  chemotherapy.  In  patients  with  primary
mmunodeﬁciencies,  standard  chemotherapy  regimens  are
ot  well  tolerated.  Anti-CD20  monoclonal  antibodies  could
chieve  complete  remission  in  patients  with  B-cell  lym-
homas  and  CVID.  Rituximab  should  be  considered  as
onotherapy  or  associated  with  a  reduced  chemotherapyegime.27--29 Two  of  our  patients  were  treated  with  ritux-
mab  as  monotherapy  achieving  a  complete  remission  and
elapse-free  after  3  and  6  years  of  follow-up,  respectively.
he  third  patient  with  MALT  lymphoma  was  initially  treatediated lymphoma tissue; EBV, Epstein-Barr virus; CHOP, cyclophos-
ith  CHOP.  Treatment  of  the  recurrence  after  4  years  of
emission  was  done  with  rituximab,  achieving  a  second  com-
lete  remission.
In  conclusion,  CVID  is  a  common  congenital  immu-
odeﬁciency  with  clinical  manifestations  of  infections,
utoimmune  diseases  and  neoplasms.  In  pediatric  patients
t  may  initially  present  as  a neoplastic  disease,  especially
HL,  and  is  frequently  associated  with  EBV  infection.  Early
etection  of  the  EBV  infections  and  the  NHL  in  all  patients
ith  diagnosis  of  CVID  is  recommended,  regardless  of  the
ge  at  diagnosis.
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